UroGen Pharma Ltd. (URGN): R&D Expense
$67.11M
Year ended 2025-12-31
$61.26M
Trailing 12 months to 2026-06-30
+8.2%
3-year compound annual growth
+7.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.11M | +17.4% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $57.15M | +25.3% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $45.61M | -13.8% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $52.91M | +11.0% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $47.64M | +0.7% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $47.31M | -4.0% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $49.30M | +33.5% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $36.93M | +97.5% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $18.70M | n/a | 2020-03-02, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $67.11M | +17.4% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $37.41M | -0.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $12.74M | -69.7% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $137.00M | +1.8% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.43M | +5.2% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $19.96M | +62.1% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $416.03M | +22.6% |
Compare URGN, TBPH, ZVRA, ZYME side by side · Screen every company in Pharmaceutical Preparations ↗